To investigate the underlying mechanism of the antidiabetic effect of VGSC blockers, Dhalla et al. found that glucagon release was mediated by the NaV1.3 channels, and selective NaV1.3 blockers might provide a novel approach for the treatment of diabetes [68]. This evidence concerns the gene SCN3A and diabetes mellitus.